Nov 24, 2024, 04:47
Zanidatamab is approved by US FDA based off Herizon BTC01
Oncology Brothers shared a post on X:
“Zanidatamab (bispecific antibody against Her2) now US FDA approved for unresectable/metastatic HER2+ biliary tract cancer based off HerizonBTC01 – Single arm Ph2B study, 20 mg/kg IV Q2W – mDoR 14.9mos – mOS 15.5mos – AEs: Diarrhea, EF.”
More posts featuring Oncology Brothers.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21